All In Biotech

Drug Trial Radar · NCT02802423

Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.

A Multi-Center, Randomized, Double Blind, Placebo-Controlled, Phase IIA Study to Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid With Adjuvant Chemotherapy in Patients With Triple Negative Breast Cancer (TNBC) After Surgery

Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

44

Planned (sponsor's estimate)

Start

Jan 1, 2027

Primary completion

Apr 30, 2028

Study completion Aug 28, 2028

Sponsor

Lead sponsor
BioLite, Inc.Industry
Sponsor type
Industry
First posted
Jun 16, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 20 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to determine the safety and recommended dose level (RDL) of BLEX 404 Oral Liquid combined with Docetaxel monotherapy in a 21-day schedule. The secondary purpose is to assess the efficacy and safety of BLEX 404 Oral Liquid combined with Docetaxel monotherapy.

Conditions

  • Triple Negative Breast Cancer

Interventions

  • BLEX 404 Oral LiquidDrug

    BLEX 404 Oral Liquid is administered twice daily during the Docetaxel monotherapy period. The dose of Docetaxel is 75 mg/m2 IV, 21 days a cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I: Dose-limiting toxicity (DLT) observationTime frame: 3 weeks (1 cycle)
  2. Phase II: Overall response rate (PR + CR)Time frame: 12 weeks (4 cycles)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.